Evidence map›Paper›PMID 35822799›Full record

ArticleBiotech (Basel (Switzerland))2021

In-Line Monitoring of Downstream Purification Processes for VSV Based SARS-CoV-2 Vaccine Using a Novel Technique.

Arik Makovitzki, Avital Jayson, Ziv Oren, Elad Lerer, Yaron Kafri, Eyal Dor, Lilach Cherry, Hanan Tzadok, Lilach Levin, Ophir Hazan and 4 more

Abstract read
In one paragraph

Article in Biotech (Basel (Switzerland)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Arik MakovitzkiDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.ORCID 0000-0003-4274-2224
Avital JaysonDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Ziv OrenDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.ORCID 0000-0001-6466-6950
Elad LererDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Yaron KafriDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Eyal DorDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Lilach CherryDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Hanan TzadokDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Lilach LevinDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Ophir HazanDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Irit SimonDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Arnon TalDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Meni GirshengornDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Osnat RosenDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.ORCID 0000-0001-7604-1755

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) increases the need for a rapid development of efficient vaccines. Among other vaccines in clinical trials, a recombinant VSV-∆G-spike vaccine was developed by the Israel Institute for Biological Research (IIBR) and is being evaluated. The development of an efficient downstream purification process (DSP) enables the vaccine to be advanced to clinical trials. The DSP must eliminate impurities, either process- or product-related, to yield a sufficient product with high purity, potency and quality. To acquire critical information on process restrictions and qualities, the application of in-line monitoring is vital and should significantly impact the process yield, product quality and economy of the entire process. Here, we describe an in-line monitoring technique that was applied in the DSP of the VSV-∆G-spike vaccine. The technique is based on determining the concentrations of metabolites, nutrients and a host cell protein using the automatic chemistry analyzer, Cobas Integra 400 Plus. The analysis revealed critical information on process parameters and significantly impacted purification processes. The technique is rapid, easy and efficient. Adopting this technique during the purification process improves the process yield and the product quality and enhances the economy of the entire downstream process for biotechnology and bio pharmaceutical products.

Indexed as

Cobas analyzerdownstream purification process (DSP)host cell proteins (HCP)lactate dehydrogenase (LDH)metabolitesnutrients

Identifiers

PMID35822799
PMCPMC9245488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.